OncoGenex Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
BOTHELL, WA. and VANCOUVER, BC – April 5, 2016 — OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that John Bencich, Chief Financial Officer at OncoGenex, will present at the 15th Annual Needham Healthcare Conference on April 13, 2016 at the Westin Grand Central Hotel in New York City.
The presentation will begin at 2:20 p.m. EDT and a live audio webcast can be accessed directly at http://wsw.com/webcast/needham76/ogxi, or from the Investor Relations page of the OncoGenex website at www.OncoGenex.com. The webcast replay will be archived for 90 days.
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development. More information is available at http:www.OncoGenex.com and on Twitter at https://twitter.com/OncoGenex_IR.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/oncogenex-pharmaceuticals-to-present-at-the-15th-annual-needham-healthcare-conference-300245760.html.